Impact of Antiobesity Medications on Appetite and Appetite-related Hormones and Metabolites.
NCT06856928 · Not yet recruiting
Last updated 2026-05-28This clinical trial is testing how anti-obesity medications affect appetite and related hormones in adults with obesity.
What this study is testing ClinicalTrials.gov NCT06856928 ↗
Description as written by the study sponsor.
This study aims to explore how anti-obesity medications (AOMs) like semaglutide and tirzepatide affect appetite and energy intake. Researchers will examine two groups: one just starting AOMs and another that has already achieved significant weight loss and maintained it. By conducting meal challenges at different stages of medication use, the study will assess feasibility of the methods and gather preliminary data to design a larger, future study.
Treatments tested
- Meal Challenge Other
The meal challenge scheduled for 4-6 days after the patient's last injection. The study team will insert an indwelling venous catheter into the participant's forearm for serial blood draws. Immediately prior to the meal, participants will consume 1500 mg of acetaminophen (off-label) to facilitate the analysis of gastric emptying. The participant will then begin the meal challenge by eating the test meal, a breakfast casserole, containing 33% of their current resting energy expenditure needs estimated by Mifflin-ST Jeor equation with a composition of 50% carbohydrate, 30% fat and 20% protein. Participants must completely consume the test meal within 25 minutes of initiating the meal. Participants will fill out behavioral questionnaires after consuming the test meal. After the 2-hour blood draw period, participants will be dismissed. Blood will be drawn prior to the meal and at 5, 10, 15, 30, 60, 90, and 120 minutes after initiating the meal.
| Main thing measured | Participant Recruitment |
|---|---|
| Sponsor | University of Colorado, Denver |
| Conditions studied | Obesity; Drug |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06856928 ↗